Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects

Psoriasis Clinical Trial

Official title:

A Randomized, Double-blinded, Single-dose, 3-arms Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2306 Injection vs Secukinumab Injection (Cosentyx®) in Healthy Chinese Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04711343
• Other study ID #: BAT-2306-001-CR
• Status: Completed
• Phase: Phase 1
• Start date: June 8, 2022
• Est. completion date: June 5, 2023

Study information

• Verified date: August 2023
• Source: Bio-Thera Solutions
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT2306 Injection vs Cosentyx® (EU-licensed and US-licensed) in healthy Chinese male subjects. A total of 216 healthy male subjects are planned to be included and randomized at a ratio of 1:1:1 to receive single 150mg BAT2306 Injection or Cosentyx® (EU-licensed and US-licensed).

Description:

The study has a screening period of 14 days. PK blood samples will be collected from subjects to determine the serum concentration of Secukinumab, thus to evaluate the similarity of the pharmacokinetics of the three study drugs.

The investigator will perform safety evaluation for vital signs, physical examinations, injection site reaction, ECG, clinical laboratory tests and adverse events throughout the study. Immunogenicity evaluation (ADA, ADA titration and NAb) will also be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 216
• Est. completion date: June 5, 2023
• Est. primary completion date: May 3, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Chinese male healthy subjects aged from 18 to 55 years (including the boundary value);

• BMI between 18-28kg/m2 (including boundary value) and body weight between 55-85kg;

• Normal physical examination results or abnormal with no clinical significance according to the doctor's judgment;

• The subject (including partner) has no pregnancy plan or sperm donation plan during the whole trial period and within 6 months after the completion of the study, and voluntarily adopts effective contraceptive measures;

• Sign the informed consent before joining the study, and fully understand the content, process and possible risks;

• Willing and able to comply with the visits and treatments of the trial protocol.

Exclusion Criteria:

• Clinical laboratory examination results are abnormal and with clinical significance, or other clinical findings indicate diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, tumor, pulmonary, immune, mental or cardiovascular and cerebrovascular diseases) with clinical significance within one year prior to screening;

• ECG is abnormal and has clinical significance (judged by the investigator);

• With active infection within two months before screening, including acute and chronic infection and local infection;

• Hepatitis B and/or Hepatitis C; or HIV antigen/antibody positive; or Treponema pallidum antibody positive;

• Having taken any prescription drug, over-the-counter drug, any vitamin product or herbal medicine within 28 days before screening (or within 5 half-lives of the above drugs, whichever is longer);

• Having participated in drug clinical trials within 3 months before the study administration, or planning to participate in other drug clinical trials during the study period;

• Acute disease occurred or with concomitant medication from the screening to use of the study drug; major injury or surgery or fracture occurred within 4 weeks before enrollment, or surgery was planned during the study;

• Having used Secukinumab (or its biosimilars) or interleukin (IL-17) targeting agents, or having used any biological products or monoclonal antibodies within 3 months before screening (or within 5 half-lives of the drugs, whichever is longer);

• Having received within 12 weeks prior to initiating treatment or planning to receive live vaccines during the study;

• Suspected or confirmed as allergic constitution (allergic to variety of drugs or food), or allergic to Secukinumab, or severe allergic or allergic reaction to monoclonal antibody;

• Blood donation or massive blood loss (> 450 ml) within 3 months before using the study drug, or planning to donate blood during the study, or having received blood transfusion within 8 weeks before screening;

• Positive urine drug screening or drug abuse history or drug use in the past five years;

• Employees or relatives of all investigators, clinical centers, clinical research organizations or sponsors cannot be included in the group;

• Subjects considered unsuitable by the investigators.

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• BAT2306
150mg/1 ml; single dose;prefilled syringe; subcutaneous injection
• Cosentyx (US-licensed)
150mg/1 ml; single dose;prefilled syringe; subcutaneous injection
• Cosentyx (EU-licensed)
150mg/1 ml; single dose;prefilled syringe; subcutaneous injection

Locations

Country	Name	City	State
China	The First Hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Bio-Thera Solutions

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics Endpoint:Peak plasma concentration (Cmax)	Pharmacokinetics Endpoint:Peak plasma concentration (Cmax)	0-5months
Primary	Pharmacokinetics Endpoint:Area under the plasma concentration versus time curve (AUC0-inf)	Pharmacokinetics Endpoint:Area under the plasma concentration versus time	0-5months